Start Disrupting

The art of partnering: How your small company can change the game for big companies

February 15, 2022 Virginia Tech Corporate Research Center Season 2 Episode 3
Start Disrupting
The art of partnering: How your small company can change the game for big companies
Show Notes

Kenna Anderes Ph.D., RAC,  Vice President of Translational Medicine & Companion Diagnostics at Mirati Therapeutics, talks →  The art of partnering: How your small company can change the game for big companies; plus, “FIO” Figure it Out, how to follow the data, and navigate complex timelines and more. 

Dr. Anderes has been a scientific leader in oncology drug discovery, biomarker identification, and early clinical development in the pharmaceutical and biotech industries for over 20 years. She is trained as a pharmacologist and cancer biologist and has held a number of senior executive and scientific advisory positions at pharmaceutical, biotech, and in vitro diagnostic companies.

As an early employee in several startup companies, Dr. Anderes acquired very broad, interdisciplinary technical and business skills, with breadth in science, clinical research, clinical operations, regulatory strategy, and product/medical device development. Achievements range from lead identification of novel small molecule or biological entities to characterization of clinical development candidates for several distinct first-in-class molecular targeted agents to treat cancer. She has extensive experience directing and designing studies to determine relationships to drug exposure, mechanism of action, efficacy, and biomarkers in the single-agent and combination settings in vitro and in vivo in classical xenografts and patient-derived tumor models. In parallel to drug discovery/development activities,

Dr. Anderes has led equally diverse biomarker and in vitro diagnostic projects. She has evaluated numerous liquid biopsy approaches and served as an advisor on pharma-sponsored clinical trials to evaluate the clinical utility of CTCs and ctDNA. Delivery on the promise of personalized medicine requires strategic and tactical translational medicine expertise, Dr. Anderes formed Translational Medicine Partners, Inc. and co-founded Wild Type Advisors, LLC to provide bespoke consulting services for the life sciences, biotechnology and pharmaceutical industries.

Host: Brett Malone
Editor and Producer: Becca Halm